News
Cytovance® Biologics to Expand Microbial Manufacturing - 04/16/2013
Oklahoma City, OK -- Cytovance® Biologics, Inc., a leading full-service contract manufacturer of mammalian and microbial biologics, announces the planned expansion of its microbial manufacturing capabilities. In addition to its current 100L Fermenter, Cytovance recently acquired a second 100L and a 1000L Fermenter. [More]
Cytovance CSO Jeffrey Su, Ph.D., to present at 5th Annual International Conference of Antibodies in China - 02/12/2013
Oklahoma City, OK -- Cytovance® Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announces that CSO Jeffrey Su, Ph.D., will speak at the 5th Annual International Conference of Antibodies in Hangzhou, China in March 2013. The presentation title is Biosimilars: Challenges and Solutions. [More]
Cytovance® Biologics to Expand Production Capabilities in 2013 - 01/29/2013
Oklahoma City, OK -- Cytovance® Biologics., a leading full-service contract manufacturer of mammalian and microbial biologics, announced today that it will expand its current mammalian production capabilities to include a 1,000L SUB bioreactor, a 5,000L stainless steel bioreactor and an automated fill/finish line. [More]
Cytovance® Biologics welcomes Maria Lopez as Vice President of Quality - 01/23/2013
Oklahoma City, Okla. -- Cytovance® Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, welcomes Maria Lopez as the Vice President of Quality. [More]
Shannon Goodson named President of the South Central ISPE Chapter - 12/11/2012
Oklahoma City, Okla. -- Shannon Goodson, Senior Process Engineer for Cytovance® Biologics, was recently named President of the South Central Chapter of ISPE, the International Society for Pharmaceutical Engineering. Her 2-year term will serve professionals in Oklahoma, Texas and Louisiana. [More]
Cytovance® Biologics, Inc. Announces Manufacturing Agreement with Selexys Pharmaceuticals Corp. for Phase II Production of SelG1 - 11/13/2012
Oklahoma City, Okla. -- Cytovance Biologics, Inc. announces an agreement with Selexys Pharmaceuticals Corp. to produce its lead asset, the SelG1 monoclonal antibody (mAb) for a Phase II clinical study in patients with sickle cell disease. [More]
Cytovance® Biologics, Inc. Awarded Biopharmaceutical Development and Manufacturing Contract by Fountain BioPharma, Inc. - 10/31/2012
Oklahoma City, Okla. -- Cytovance Biologics, Inc. and Fountain BioPharma, Inc. jointly announce the execution of a Biopharmaceutical Development and Manufacturing collaboration for FB301, a novel monoclonal antibody (mAb) being developed for the treatment of allergy as a lead indication. [More]
Cytovance® Biologics scores improved Customer Perception ratings - 10/09/2012
Oklahoma City, Okla. -- Data from a recent strategic partnering survey by Nice Insight boasts a rating increase in reliability and quality for Cytovance Biologics. [More]
Selexys Pharmaceuticals wins investment, Cytovance Biologics continues as contract manufacturer - 9/19/2012
Oklahoma City, Okla. -- Cytovance Biologics client Selexys Pharmaceuticals has acquired $23 million in venture capital financing with MPM Capital and entered into an agreement with Novartis Pharmaceuticals that could reach up to $665 million. [More]
Cytovance® Biologics receives 2012 CMO Leadership Award for Reliability - 9/18/2012
Oklahoma City, Okla. -- Cytovance® Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, announced today its receipt of the 2012 CMO Leadership Award as a category leader for Reliability. The CMO Leadership Award is based on industry research conducted by Nice Insight and presented by Life Science Leader Magazine. [More]
Cytovance® Biologics Announces Don Wuchterl as Senior Vice President of Manufacturing Operations - 07/30/12
Oklahoma City, OK -- Cytovance® Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces Don Wuchterl as the new Senior Vice President of Manufacturing Operations. [More]
Cytovance® Biologics Announces New Corporate Logo and Website - 07/02/12
Oklahoma City, OK -- Cytovance® Biologics, a leading full-service contract manufacturer of mammalian and microbial biologics, reveals a new corporate logo and a new company website as part of the ongoing evolution of the company’s brand. [More]
Darren Head interviewed in GEN's "Changing Landscape for Contract Manufacturers" - 07/01/12
New Rochelle, NY -- Cytovance® Biologics' President and CEO, Darren Head, was one of nine experts recently interviewed by Genetic Engineering & Biotechnology News on the evolution of contract manufacturing over the past decade. [More]
BiologicsMD, Inc. Awards Manufacturing Contract to Cytovance Biologics, Inc. to Expand Development of Breakthrough Osteoporosis Medication - 06/12/12
Fayetteville, Ark. -- BiologicsMD, a drug development company based in Fayetteville, AR., awarded a manufacturing contract to Cytovance Biologics, Inc. located in Oklahoma City, OK, to continue development of BiologicMD’s breakthrough osteoporosis medication, PTH-CBD™. [More]
Cytovance® Biologics Names Martin LeBlanc to Board of Directors - 05/08/12
Oklahoma City, OK -- Cytovance® Biologics, a leading full-service contract manufacturer (“CMO”) of mammalian and microbial biologics, announces the appointment of Martin LeBlanc to the company’s Board of Directors. [More]
Cytovance® Biologics Receives 2012 Best of Oklahoma City Award - 03/23/12
New York, NY -- Cytovance has been selected for the 2012 Best of Oklahoma City Award in the Druggists' Preparations category by the U.S. Commerce Association (USCA). [More]
Cytovance® Biologics Strengthens Management Team- 03/15/12
Oklahoma City, OK -- Cytovance® Biologics strengthens its management leadership in the departments of finance, operations and business development. [More]
Cytovance® Biologics Manufacturing Capacity Grows- 01/27/12
Oklahoma City, OK - Cytovance® Biologics announced today that it is has added a 1,000L bioreactor to its current mammalian facility with appropriate downstream processing facilities. [More]
Cytovance® Biologics Hires Valerie McDonnell as Vice President of Sales and Business Development- 01/26/12
OKLAHOMA CITY, OK – Cytovance Biologics, Inc. announces the addition of Valerie McDonnell as Vice President of Sales and Business Development. [More]
Cytovance® Biologics secures a staged $22.5 million equity investment- 03/15/11
Oklahoma City, OK -- Cytovance Biologics secures a staged $22.5 million equity investment to expand its biologic manufacturing capabilities in Oklahoma City [More]
Cytovance® Biologics Awarded Biopharmaceutical Development, Manufacturing Contract by Selexys Pharmaceutical Corporation - 04/27/10
Oklahoma City, OK -- Cytovance Biologics LLC Awarded Biopharmaceutical Development and Manufacturing Contract by Selexys Pharmaceutical Corporation [More]
DASGIP Spotlight: Fed Batch Process Scale Up from 0.6 to 100L - 03/18/10
Life Technologies PD-Direct® partnered with Cytovance Biologics to demonstrate rapid process transfer and scale up [More]